Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

Collection UNKNOWN
H. Sheehy, Susanne; J. A. Duncan, Christopher; C. Elias, Sean; Biswas, Sumi; A. Collins, Katharine; A. O'Hara, Geraldine; D. Halstead, Fenella; J. Ewer, Katie; Mahungu, Tabitha; J. Spencer, Alexandra; Miura, Kazutoyo; D. Poulton, Ian; D. J. Dicks, Matthew; J. Edwards, Nick; Berrie, Eleanor; Moyle, Sarah; Colloca, Stefano; Cortese, Riccardo; Gantlett, Katherine; A. Long, Carole; M. Lawrie, Alison; C. Gilbert, Sarah; Doherty, Tom; Nicosia, Alfredo; V. S. Hill, Adrian; J. Draper, Simon;
  • Publisher: Figshare
  • Related identifiers: doi: 10.1371/journal.pone.0031208
  • Subject: Microbiology | antigen | immunogenicity | blood-stage | ama1 | vectors | chad63 | ia | mva | Cancer | Immunology
    mesheuropmc: complex mixtures | parasitic diseases

<div><h3>Background</h3><p>Traditionally, vaccine development against the blood-stage of <em>Plasmodium falciparum</em> infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to dat... View more
Share - Bookmark

  • Download from
    figshare via figshare (Collection, 2012)
  • Cite this research product